Feature | December 06, 2013

Stroke Mortality is Down, but the Reason Remains a Mystery

stroke treatment devices clinical trial study alabama
December 6, 2013 — A national group of leading scientists, including one University of Alabama at Birmingham (UAB) expert, said that for more than 100 years, fewer people have been dying of stroke, yet it is still unclear why this decline remains constant.
 
The American Heart Assn. (AHA) and American Stroke Assn. have published a scientific statement, “Factors Influencing the Decline in Stroke Mortality,” which has also been affirmed by the American Academy of Neurology as an educational tool for neurologists. The statement is published in the AHA journal Stroke.
 
Stroke is a leading cause of long-term disability and was previously recognized as the third leading cause of death in the United States, according to the National Stroke Association. However, stroke has now fallen to the fourth leading cause of death due to decreases in people dying from it. This has led the Centers for Disease Control and Prevention to acknowledge the decline and a similar decline in heart disease as one of the 10 great achievements in public health of the 20th century.
 
George Howard, Dr.P.H., professor, department of Biostatistics, School of Public Health, UAB, and statement co-author explained that, even with these dramatic decreases, there is still more to be done.
 
“Stroke has been declining since 1900, and this could be a result of changes leading to fewer people having a stroke or because people are less likely to die after they have a stroke,” said Howard. “Nobody really knows why, but several things seem to be contributing to fewer deaths from stroke.”
 
Perhaps the biggest contributor to the decline, Howard said, are changes leading to lower blood pressure levels, which is the biggest of the stroke risk factors. Other contributors may include reductions in smoking, better treatment of cholesterol and how people are cared for after having a stroke.
 
“We don’t know how much all of the sources are contributing,” said Howard. “Certainly, we want it to keep going down; but if we don’t understand why the numbers are decreasing, we can’t work toward that trend.”
 
Howard said that, in the last 11 years, stroke deaths have declined by 30 percent.
 
“It’s a big deal, so you could argue that our battle is won,” he said. “But I think we still have a lot to be accomplished in this area.”
 
Andrei Alexandrov, M.D., professor of neurology and director, UAB Comprehensive Stroke Center, was not affiliated with the statement but said it brings welcome news.
 
“This likely is attributable not only to better arterial blood pressure control over recent years, but also to a greater number of neurological specialists focused on stroke care across many hospitals in the United States and abroad,” said Alexandrov. “Better early stroke recognition and specialized care can also reduce the risk of dying from stroke.”
 
Alexandrov pointed out one finding of the statement — the lower death rate among adults younger than 65 years of age — deserves further attention since a large proportion of stroke victims in the Southeastern United States are young.
 
“More efforts are needed to reduce mortality and prevent first-ever stroke incidence, as well as to reverse disability following stroke by improving patient access to hospitals providing clot-busting therapy,” said Alexandrov.
 
Howard agrees that, while stroke prevention and care have played a large part in the decline of stroke mortality, more research needs to be done in stroke prevention.
 
“This brings up an interesting question: should more research resources go toward areas where we’ve seen success, or should they go where differences haven’t been made yet?” said Howard. “I’d say there’s an argument for both.”
 
For more information: www.uab.edu

Related Content

St. Jude Medical, HeartMate 3 LVAS, MOMENTUM 3 IDE study results, AHA Scientific Sessions 2016
News | Ventricular Assist Devices (VAD)| December 08, 2016
St. Jude Medical Inc. announced results of the MOMENTUM 3 U.S. IDE Clinical Study during a late-breaking clinical trial...
PET, F-18 florbetaben, cardiac amyloidosis, Princess Alexandria Hospital

In a pilot study, F-18-florbetaben PET imaging appeared promising for differentiating between cardiac amyloidosis and hypertensive heart disease. Image courtesy of W. Phillip Law/Princess Alexandra Hospital, Brisbane, Australia.

News | Nuclear Imaging| December 06, 2016
Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal...
coronary CT angiography, CCTA, alcohol consumption, CAD, coronary artery disease, RSNA 2016
News | CT Angiography (CTA)| November 29, 2016
Researchers using coronary computed tomography angiography (CCTA) found no association between light to moderate...
News | Cath Lab| November 21, 2016
November 21, 2016 – A single-center study sponsored by the National Institutes of Health (NHLBI) failed to show an ea
InspireMD, CGuard embolic protection system, EPS, clinical data, internal carotid artery stenosis, ICA
News | Stents Carotid| November 18, 2016
November 18, 2016 — InspireMD Inc.
Boston Scientific, HeartLogic Heart Failure Diagnostic Service, MultiSENSE trial data, AHA Scientific Sessions 2016
News | Heart Failure| November 18, 2016
Boston Scientific recently announced results from the first clinical trial evaluating the performance of the HeartLogic...
cardiac rehabilitation, depression, death risk, heart surgery, Intermountain Medical Center Heart Institute, AHA Scientific Sessions 2016
News | Cardiac Rehabilitation| November 15, 2016
Depression has been known to be associated with poor cardiovascular outcomes. But if patients who are depressed attend...
atrial fibrillation, warfarin, dementia, Intermountain Medical Center Heart Institute, American Heart Association, AHA Scientific Sessions 2016
News | Atrial Fibrillation| November 15, 2016
Atrial fibrillation patients who use warfarin to lower risk of stroke are at higher risk of developing dementia than...
PET/CT, calcium blockages, heart attack risk, Intermountain study, American Heart Association, AHA Scientific Sessions 2016
News | PET-CT| November 15, 2016
Many people who experience chest pain but don’t have a heart attack breathe a big sigh of relief when a stress test...
bivalirudin, heparin, blood clot prevention medication, PCI, percutaneous coronary intervention, Intermountain study, AHA Scientific Sessions
News | Antiplatelet and Anticoagulation Therapies| November 14, 2016
Two differing blood clot prevention medications are just as safe and effective for patients undergoing percutaneous...
Overlay Init